## Vibe Growth Corporation

## Condensed Consolidated Financial Statements (Unaudited)

As at and for the Three and Six Months Ended June 30, 2021 (In U.S. Dollars, Unless Otherwise Noted)

## Notice for National Instrument 51-102

The accompanying unaudited interim condensed consolidated financial statements of Vibe Growth Corporation as at and for the three and six months ended June 30, 2021, have been prepared by management and approved by the Audit Committee and the Board of Directors of the Company. These statements have not been reviewed or audited by the Company's external auditors.



## Vibe Growth Corporation Unaudited Condensed Consolidated Statements of Financial Position (Expressed in U.S. dollars)



		June 30,	December 31,
As at	notes	2021	2020
Assets			
Current assets			
Cash and cash equivalents		\$ 12,992,316	\$ 2,412,798
Accounts receivable		222,234	21,428
Inventory	4	3,892,363	3,162,192
Biological assets	5	483,501	270,290
Other current assets		516,286	341,906
Total current assets		18,106,700	6,208,614
Intangible assets and goodwill	6	8,304,897	6,541,457
Property and equipment	7	5,446,587	4,668,162
Right-of-use assets	8	1,634,268	923,957
Total assets		\$ 33,492,452	\$ 18,342,190
Liabilities			
Current liabilities			
Accounts payable		\$ 2,842,519	\$ 2,853,930
Income taxes payable		4,206,053	1,991,662
Current portion of lease obligations and notes			
payable	9, 10	649,244	499,160
Total current liabilities		7,697,816	5,344,752
Notes payable	10	1,361,105	1,427,346
Lease obligations	9	1,191,898	642,739
Deferred tax liability		813,486	817,138
Total liabilities		\$ 11,064,305	\$ 8,231,975
Shareholders' equity			
Share capital	11(a)	\$ 28,715,322	\$ 19,686,343
Warrants	11(b)	3,649,516	349,757
Contributed surplus		1,530,991	1,462,889
Accumulated other comprehensive loss		(190,658)	(144,330)
Deficit		(11,277,024)	(11,244,444)
		22,428,147	10,110,215
Total liabilities and shareholders' equity		\$ 33,492,452	\$ 18,342,190

Contingencies (Note 14)

Subsequent events (Note 16)

# Vibe Growth Corporation Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Expressed in U.S. dollars)



		For the three months ended June 30,			For the six months ended June 30,				
	notes		2021		2020		2021		2020
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of fair value adjustments for biological assets	4	\$	7,791,690 5,261,996 2,529,694 25,601	\$	5,683,529 3,772,828 1,910,701 134,071	1	15,334,425 10,323,807 5,010,618 109,389	\$	9,956,127 6,579,709 3,376,418 136,113
Gross margin		_	2,555,295	_	2,044,772		5,120,007	_	3,512,531
Operating expenses General and administrative Sales, security and marketing Stock-based compensation Depreciation and amortization	11(c) and (d) 6, 7, 8		772,878 886,182 143,661 283,474	_	679,221 660,333 24,375 180,655		1,539,933 1,762,003 241,601 533,204		1,301,533 1,234,240 59,664 351,930
		_	2,086,195	_	1,544,584	_	4,076,741	_	2,947,367
Other expenses (income) Bargain purchase gain Listing fee Transaction expenses Finance expense Other (income) expense	3 9 and 10		34,800 59,162 (8,300) 85,662	_	(344,051) 9,500 - 33,137 (110,753) (412,167)		34,800 107,895 (15,836) 126,859		(344,051) 9,500 - 65,177 (122,146) (391,520)
Income before income taxes			383,438		912,355		916,407		956,684
Income tax expense (recovery) Current Deferred		_	509,766 (25,503) 484,263		456,370 (21,829) 434,541		998,766 (49,779) 948,987	_	744,564 (43,363) 701,201
Net income (loss) for the period			(100,825)		477,814		(32,580)		255,483
Other comprehensive loss Foreign currency translation gain (loss)  Net income (loss) and comprehensive income (loss) for the period		<u> </u>	95,571 (5,254)	\$	(16,989) 460,825	<u> </u>	(46,328) (78,908)	\$	(56,939) 198,544
Income (Loss) per share Basic and Diluted Diluted		\$ \$ \$	(0.001)	\$	0.006	\$ \$	-	\$ \$	0.003
Weighted average shares outstanding  Basic  Diluted			02,893,794 02,893,794		78,014,379 78,014,379		94,592,101 94,592,101		77,795,795 77,795,795

# Vibe Growth Corporation Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Expressed in U.S. dollars)



	Common		Total
	share	Contributed	shareholders'
	capital Warrants	surplus AOCI*	Deficit equity
Balance at December 31, 2020	\$ 19,686,343 \$ 349,757	\$ 1,462,889 \$ (144,330)	\$ (11,244,444) \$ 10,110,215
Shares issued in equity financing	9,964,306 2,842,145		- 12,806,451
Agents commission	205,213 59,614		- 264,827
Share issue costs	(1,529,247) 445,512		- (1,083,735)
Exercise of stock options	205,213 -	(173,499) -	- 31,714
Exercise of warrants	183,494 (47,512		- 135,982
Stock-based compensation		241,601 -	- 241,601
Net and comprehensive income (loss)	<u>-</u>	- (46,328)	(32,580) (78,908)
Balance at June 30, 2021	\$ 28,715,322 \$3,649,516	\$ 1,530,991 \$ (190,658)	<u>\$ (11,277,024)</u>
Balance at December 31, 2019	\$ 17,651,013 \$ 25,227	\$ 1,379,539 \$ (79,772)	\$ (11,972,994) \$ 7,003,013
Shares issued in business acquisitions	132,000 -		- 132,000
Shares issued for services rendered	35,355 -		- 35,355
Share issue costs	(2,200) -		- (2,200)
Exercise of stock options	66,751 -	(65,981) -	- 770
Expiry of warrants	- (25,227	25,227 -	-
Stock-based compensation		59,664 -	- 59,664
Net and comprehensive income (loss)	<u> </u>	(56,939)	255,483 <b>198,544</b>
Balance at June 30, 2020	<u>\$ 17,882,919</u>	<u>\$ 1,398,449</u> <u>\$ (136,711)</u>	<u>\$ (11,717,511)</u> <u>\$ 7,427,146</u>

## Vibe Growth Corporation Unaudited Consolidated Statements of Cash Flows (Expressed in U.S. dollars)



	For the three months ended			For the six months ended				
	June 30,				June	30	,	
		2021		2020		2021		2020
Operating activities								
Net income (loss) for the period	\$	(100,825)	\$	477,814	\$	(32,580)	\$	255,483
Items not involving cash:								
Listing fee		-		9,500		-		9,500
Unrealized (gain) loss on changes in the fair value of biological assets		(25,601)		(134,071)		(109,389)		(136,113)
Stock-based compensation		143,661		24,375		241,601		59,664
Bargain purchase gain		-		(344,051)		-		(344,051)
Depreciation and amortization		283,474		180,655		533,204		351,930
Unrealized foreign exchange gain (loss)		56,376		22,004		191,781		74,620
Deferred income tax recovery		(25,503)		(21,829)		(49,779)	_	(43,363)
Change in non-cash working capital:		331,582		214,397		774,838		227,670
Accounts receivable		(193,109)		(2,252)		(200,806)		92,978
Inventory		(162,933)		(834,065)		(502,397)		(1,083,025)
Biological assets		(180,719)		(32,146)		(305,616)		23,392
Other current assets		(172,701)		(184,853)		(174,380)		(168,055)
Accounts payable and accrued liabilities		787,279		1,057,958		(11,411)		648,368
Income taxes payable		508,999		457,170		998,003		738,789
Cash flow provided from (used in) operating activities		918,398	_	676,209	_	578,231	_	480,117
Investing activities								
Cash (paid) on business acquisitions, net of cash acquired		(380,000)		(111,884)		(380,000)		(111,884)
Intangible assets purchased		-		-		(330,000)		-
Purchases of property and equipment		(801,613)		(99,483)		(914,005)	_	(232,046)
Cash flow provided from (used in) investing activities		(1,181,613)		(211,367)		(1,624,005)		(343,930)
Financing activities								
Issuance of common shares and warrants		128,816		770		12,155,239		770
Repayment of lease obligation		(337,986)		(51,926)		(416,824)		(103,371)
Repayment of notes payable		(89,955)		(8,766)		(133,986)		(21,559)
Cash flow provided from (used in) financing activities		(299,125)		(59,922)		11,604,429	_	(124,160)
Effect of translation of cash held in foreign currencies		153,162	_	72,307		20,863	_	(19,025)
Increase (decrease) in cash and cash equivalents		(409,178)		477,227		10,579,518		(6,998)
Beginning cash and cash equivalents	:	13,401,494		1,153,271		2,412,798		1,637,496
Ending cash and cash equivalents	\$ :	12,992,316	\$	1,630,498	\$	12,992,316	\$	1,630,498
Supplemental cash flow information								
Interest paid in the period	\$	59,162	\$	33,698	\$	107,895	\$	65,177
Income taxes paid in the period	\$	-	\$	5,775	\$	-	\$	5,775



#### 1. NATURE OF OPERATIONS

Vibe Growth Corporation (the "Company" or "Vibe") business is to evaluate, acquire and develop cannabis cultivation, distribution and manufacturing assets and retail cannabis dispensaries, predominantly in the U.S., in order to become a vertically integrated cannabis operator. The Company currently operates four dispensaries, one distribution and two cultivation operations in the State of California plus one dispensary in Portland, Oregon. The Company's registered office is located at #301, 1665 Ellis Street Kelowna, British Columbia V1Y 2B3 and its U.S. head office is located at 8112 Alpine Ave Sacramento, California 95826. The Company's common shares trade on the Canadian Securities Exchange under the ticker symbol "VIBE."

#### 2. BASIS OF PRESENTATION

## (a) Statement of compliance

These condensed interim consolidated financial statements ("consolidated financial statements") have been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting. These financial statements were authorized for issue by the Board of Directors on August 25, 2021. They do not contain all disclosures required by IFRS for annual financial statements and, accordingly, should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020. These condensed consolidated financial statements have been prepared using accounting policies consistent with those used in the annual consolidated financial statements.

### (b) Measurement basis

These condensed consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments that have been measured at fair value and specifically noted within the notes to these condensed consolidated financial statements.

### (c) Functional and presentation currency

These condensed consolidated financial statements are presented in United States Dollars. The Canadian Dollar is the functional currency of the Company and its Canadian wholly own subsidiaries. The functional currency of the Company's subsidiaries operating in the United States is the United States Dollar.

For reporting purposes, the assets and liabilities of the Company and its Canadian subsidiaries are translated into United States Dollars at the closing rate at the date of the balance sheets, and revenue and expenses are translated at the average rate for the period. Foreign currency translation adjustments are recorded in other comprehensive income (loss).

### (d) Covid-19

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This pandemic, which has continued to spread through variants, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally. It is not possible for the Company to predict the duration or magnitude of the adverse results of the pandemic and its effects on the Company's business or ability to raise funds. The State of California has deemed the sale of cannabis an essential service allowing the Company to keep its dispensaries open and maintain its cultivation operations. The Company will continue to follow the guidance of local, state, national and international health authorities to make informed decisions and provide its clients and staff with information as the Company's priority is on the safety and well-being of its employees and clients.



### (e) Basis of consolidation

These condensed consolidated financial statements include the accounts of the Company and the following subsidiaries:

Subsidiary	Jurisdiction of incorporation
·	
Vibe Investments, LLC	Nevada, U.S.A
Vibe by California Inc. (formerly Vibe Bioscience Inc.) ("Vibe U.S.")	Nevada, U.S.A
Hype Bioscience Corporation ("Hype Canada")	Alberta, Canada
Hype Holdings, LLC	California, U.S.A
Port City Alternative of Stockton Inc. ("Port City")	California, U.S.A
Alpine Cultivation LLC (formerly Alpine CNAA LLC ) ("Alpine Cultivation")	California, U.S.A
Alpine Alternative Naturopathic Inc. ("Alpine Alternative" or "Sacramento")	California, U.S.A
EVR Managers LLC ("Redding")	California, U.S.A
NGEV Inc. ("NGEV" or "Crescent City")	California, U.S.A
Vibe Ukiah, LLC (formerly Vibe Desert) ("Ukiah")	California, U.S.A
Cathedral Asset Holding Corporation ("CAHC")	California, U.S.A
Vibe Salinas, LLC ("Salinas")	California, U.S.A
Desert Organic Solutions Inc. ("Palm Springs")	California, U.S.A
Portland Asset Holding Corporation ("PAHC")	Oregon, U.S.A
Vibe CBD, LLC ("Vibe CBD")	California, U.S.A

All subsidiaries are wholly-owned by the Company. Subsidiaries are consolidated from the date of acquisition, being the date on which the Company obtains control, and continue to be consolidated until the date that such control ceases. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. All significant intercompany accounts and transactions have been eliminated.

## (f) Use of estimates and judgments

The preparation of the condensed consolidated financial statements requires management to make estimates and use judgment regarding the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. By their nature, estimates are subject to measurement uncertainty and changes in such estimates in future periods could require a material change in the financial statements. Accordingly, actual results may differ from the estimated amounts as future confirming events occur. Significant estimates and judgments made by management in the preparation of these condensed consolidated financial statements are as follows:

### Biological assets and inventory

In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis plants to the point of harvest, harvesting costs, and selling costs. In calculating final inventory values, management is required to determine an estimate of obsolete inventory and an estimate for any inventory for which cost is lower than estimated net realizable value and recognizes inventory provisions accordingly.



#### **Business combinations**

Judgement is required when assessing i) whether or not the acquisition of assets meets the criteria of a business combination; ii) the value of the consideration transferred and the net identifiable assets acquired and liabilities assumed in connection with business combinations and iii) determining goodwill or a bargain purchase gain.

## Discount rate for leases

Leases requires lessees to discount lease payments using the rate implicit in the lease if that rate is readily available. If that rate cannot be readily determined, the lessee is required to use its incremental borrowing rate. The Company generally uses the incremental borrowing rate when initially recording real estate leases as the implicit rates are not readily available as information from the lessor regarding the fair value of underlying assets and initial direct costs incurred by the lessor related to the leased assets is not available. The Company determines the incremental borrowing rate as the interest rate the Company would pay to borrow over a similar term the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.

## Estimated useful lives and depreciation of property, equipment and intangible assets

Depreciation of property, equipment and intangible assets is dependent upon estimates of useful lives which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.

## Cash Generating Unit ("CGU")

IFRS requires that the Company's cannabis operations be aggregated into CGUs, based on their ability to generate largely independent cash flows, which are used to assess the dispensaries and cultivation operations for impairment. The determination of the Company's CGUs is subject to management's judgment.

#### Impairment of property, equipment, intangible assets and goodwill

Indicators of impairment are assessed by management using judgement, considering future plans, market conditions and cannabis prices. In assessing the recoverability, each CGU's carrying value is compared to its recoverable amount, defined as the greater of its fair value less cost to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a post-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

## Income taxes

The Company recognises deferred tax assets to the extent that it is probable that the deductible temporary differences will reverse in the foreseeable future and that sufficient taxable income will be generated in the future to recover such deferred tax assets. Assessing the recoverability of deferred tax assets requires the Company to make significant estimates related to expectations of future taxable income. Estimates of future taxable income are based on forecast cash flows from operations and the application of existing tax laws. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realise the net deferred tax assets recorded at the reporting date could be impacted. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods.



### Provisions and contingencies

The Company recognizes provisions based on an assessment of its obligations and available information. Any matters not included as provisions are uncertain in nature and cannot be reasonably estimated.

The Company makes assumptions to determine whether obligations exist and to estimate the amount of obligations that we believe exist. In estimating the final outcome of litigation, assumptions are made about factors including experience with similar matters, past history, precedents, relevant financial, scientific, and other evidence and facts specific to the matter. This determines whether a provision or disclosure in the financial statements is needed.

## Stock-based compensation and warrants

The amounts recorded in respect of share-based compensation and share purchase warrants granted and the derivative liability for non-compensation warrants issued are based on the Company's estimation of their fair value, calculated using assumptions regarding the life of the option or warrant, interest rates and volatility. By their nature, these estimates and assumptions are subject to uncertainty, and the actual fair value of options or warrants may differ at any time.

#### Functional currency

Management judgement is required in determining the functional currency that represents the economic environment of underlying transactions, events and conditions.

### 3. BUSINESS COMBINATION

On May 4, 2021, the Company acquired all the existing shares of Desert Organic Solutions Inc. ("Palm Springs") in exchange for a cash payment of \$380,000 and assumption of tax liabilities estimated at \$1,221,000. The acquisition was treated as a business combination with the allocation of the purchase price based on the assessment of the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date. The fair values of the identifiable assets acquired and liabilities assumed as well as the purchase consideration transferred are presented below.

		May 4, 2021
Net assets acquired:		
Working capital, excluding cash	\$	(1,206,388)
Property and equipment		7,032
Right-of-use asset		231,645
Intangible assets		154,789
Goodwill		1,470,694
Deferred income taxes		(46,127)
Lease obligations		(231,645)
Fair value of the net assets acquired	<u>\$</u>	380,000
Consideration:		
Cash	<u>\$</u>	380,000

The acquisition contributed revenue of \$120,042 and an operating loss before taxes of \$27,398 from the date of acquisition to June 30, 2021. The Company estimates that had the acquisitions occurred on January 1, 2021, the increase in revenue would be approximately \$260,000 and operating profit would have decreased by approximately



\$11,900 for the six month period ended June 30, 2021. To complete the transaction the Company incurred transaction costs of \$34,800.

The transaction is accounted for using the acquisition method. Allocation of the purchase price is based on a provisional assessment of the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date and is subject to change. Management is continuing to review and assess information to accurately determine the acquisition date fair value of the assets and liabilities acquired. During the measurement period, the Company will continue to obtain information to assist in finalizing the fair value of net assets acquired, which may differ materially from the above preliminary estimates.

#### 4. INVENTORY

The Company's inventory consists of the following:

	 June 30, 2021	De	2020 <u>2020</u>
Harvested cannabis - raw materials	\$ 164,878	\$	267,173
Work-in-progress	810,830		488,612
Cannabis related products and packaging	 2,916,655		2,406,407
	\$ 3,892,363	\$	3,162,192

The Company regularly performs a review of slow moving, obsolete and redundant items and records a provision for such amounts to reflect inventory balances at net realizable value. There were no slow moving, obsolete or redundant items of inventory at June 30, 2021.

#### 5. BIOLOGICAL ASSETS

Biological assets consist of cannabis plants in the cultivation division. The changes in the carrying value of the biological assets are as follows:

	June 30, 2021		De	2020 2020
Balance, beginning of period	\$	270,290	\$	176,767
Biological assets acquired in acquisitions and business combinations		-		162,749
Changes in fair value less cost to sell due to biological transformation		109,389		346,438
Production costs		1,226,658		1,474,974
Transferred to inventory upon harvest		(1,122,836)		(1,890,638)
Balance, end of period	\$	483,501	\$	270,290

The Company values biological assets at the end of each reporting period at fair value less costs to sell ("FVLCS"). The determination of fair value less costs to sell is based on a valuation model that estimates the expected harvest yield per plant applied to the estimated wholesale price per gram, less estimated selling costs. The model also considers the stage of the biological asset in the aggregate plant life cycle.



The valuation model includes the following estimates, all of which are Level 3 inputs in the fair value hierarchy:

- (i) Average number of weeks in the growing cycle (from propagation to harvest) = 17 to 20 weeks based on historical results.
- (ii) Average selling price of whole flower = \$3.00 to \$5.00 per gram based on historical and expected future sales.
- (iii) Average harvest yield of whole flower = 50 to 80 grams per plant, net of expected wastage, based on historical results.
- (iv) Selling costs (shipping, order fulfillment, and labelling) = \$0.50 per gram based on historical results.

The above inputs are subject to volatility and uncontrollable factors which could significantly affect the fair value of biological assets in future periods. Management has quantified the sensitivity of the inputs on the calculation of the fair value of the biological assets for the respective period ended is as follows:

	 Change in FVLCS at				
	 June 30, 2021	December 3 2020			
Input					
Selling price per gram - 10% change	\$ 60,000	\$	32,500		
Harvest yield per plant - 10% change	\$ 50,000	\$	27,000		

At June 30, 2021, the average stage of completion of the biological assets is 58% based on the number of days remaining to harvest. The estimated FVLCS of dry cannabis at June 30, 2021 is approximately \$118 per plant and the expected total yield is approximately 133,000 grams of cannabis.



## 6. INTANGIBLE ASSETS AND GOODWILL

Intangible assets and goodwill consist of the following:

	Intangible assets								
		Licenses Softwa		oftware	Trademark			Goodwill	Total
Cost									
Balance at December 31, 2019	\$	5,631,482	\$	192,472	\$	78,500	\$	5,417,473	\$ 11,319,927
Acquired in asset acquistion		339,193		-		-		-	339,193
Acquired in business acquisitions		405,392		-		-		633,952	 1,039,344
Balance at December 31, 2020		6,376,067		192,472		78,500		6,051,425	12,698,464
Acquired in business acquisitions		154,789		-		-		1,470,694	1,625,483
Purchased		330,000		-		-			 330,000
Balance at June 30, 2021	\$	6,860,856	\$	192,472	\$	78,500	\$	7,522,119	\$ 14,653,947
Accumulated amortization									
Balance at December 31, 2019		2,896,879		192,472		6,968		2,729,960	5,826,279
Amortization expense		322,856		-		7,872			 330,728
Balance at December 31, 2020		3,219,735		192,472		14,840		2,729,960	6,157,007
Amortization expense		188,150		-		3,893		-	192,043
Balance at June 30, 2021	\$	3,407,885	\$	192,472	\$	18,733	\$	2,729,960	\$ 6,349,050
Net book value at December 31, 2020	\$	3,156,332	\$		\$	63,660	\$	3,321,465	\$ 6,541,457
Net book value at June 30, 2021	\$	3,452,971	\$	-	\$	59,767	\$	4,792,159	\$ 8,304,897

The Company assesses whether there are events or changes in circumstances that would more likely than not reduce the fair value of any of its reporting units below their carrying values and therefore, require goodwill and intangibles to be tested for impairment at the end of each period. As at June 30, 2021, no impairment indicators exist.



## 7. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	F	Buildings	Land	Equipment and other	nstruction process	Total
Cost			 		 - риссосс	 
Balance at December 31, 2019		2,334,084	800,000	210,866	359,470	3,704,420
Acquired in business acquisitions		-	-	681,056	-	681,056
Purchases		-	-	362,401	254,876	617,277
Transfers from construction in process		-	-	359,470	(359,470)	-
Impact of foreign exchange			 	(146)	 	 (146)
Balance at December 31, 2020	\$	2,334,084	\$ 800,000	\$1,613,647	\$ 254,876	\$ 5,002,607
Acquired in business acquisitions		-	 -	7,032	 -	 7,032
Purchases		371,791	92,948	222,475	248,975	936,189
Transfers from construction in process		-	-	335,950	(335,950)	-
Impact of foreign exchange			 	458	 -	 458
Balance at June 30, 2021	\$	2,705,875	\$ 892,948	\$2,179,562	\$ 167,901	\$ 5,946,286
Accumulated amortization						
Balance at December 31, 2019		55,248	-	49,221	-	104,469
Depreciation expense		47,984	-	182,099	-	230,083
Impact of foreign exchange			 	(107)	 	 (107)
Balance at December 31, 2020	\$	103,232	\$ 	\$ 231,213	\$ -	\$ 334,445
Depreciation expense		23,795	 -	141,888	 -	165,683
Impact of foreign exchange			 	(429)	 	 (429)
Balance at June 30, 2021	\$	127,027	\$ 	\$ 372,672	\$ 	\$ 499,699
Net book value at December 31, 2020	\$	2,230,852	\$ 800,000	\$1,382,434	\$ 254,876	\$ 4,668,162
Net book value at June 30, 2021	\$	2,578,848	\$ 892,948	\$1,806,890	\$ 167,901	\$ 5,446,587

The buildings in Sacramento hold the Sacramento cultivation and dispensary locations acquired in the Vibe Cultivation LLC and Alpine Alternative acquisitions. In April 2021, the Company acquired land and a building for Ukiah. Buildings and equipment and other assets are depreciated on a straight-line basis over their estimated useful lives. Land is not depreciated.

Assets under construction consist of improvements and renovations being completed on the Company's buildings or at leased premises. The construction and upgrades are not yet complete and will not be subject to depreciation until the underlying asset is available for use. The Company did not dispose of any property and equipment in the six month period ended June 30, 2021 and there were no impairments of property and equipment at June 30, 2021.



### 8. RIGHT-OF-USE ASSETS

Right-of-use assets consist of the following:

	Dispensary Leases		
Cost			
Balance at December 31, 2019	\$ 851,423		
Acquired in business acquisitions	352,296		
Acquired in asset acquisition	133,346		
Balance at December 31, 2020	1,337,065		
Acquired	885,789		
Balance at June 30, 2021	\$2,222,854		
Accumulated depreciation			
Balance at December 31, 2019	\$ 181,543		
Depreciation expense	231,565		
Balance at December 31, 2020	413,108		
Depreciation expense	175,478		
Balance at June 30, 2021	\$ 588,586		
Net book value at December 31, 2020	\$ 923,957		
Net book value at June 30, 2021	\$1,634,268		

## 9. LEASE OBLIGATIONS

A reconciliation of the discounted lease obligation is set forth below:

	 June 30, 2021	De	cember 31, 2020
Balance, beginning of the period	\$ 950,925	\$	688,667
Acquired in business acquisitions	231,645		352,296
Acquired in asset acquistion	-		133,346
Additions to leased assets	885,790		-
Principal paid	 (416,824)		(223,384)
Balance, end of the period	1,651,536		950,925
Less current portion of lease obligation	 (459,638)		(308,186)
Lease obligations	\$ 1,191,898	\$	642,739

Neither of the leases contain purchase or early termination options and there are no requirements to purchase the underlying assets or any residual value guarantees at the end of the leases. In 2021, the Company incurred \$55,813 of interest with respect to the aforementioned leases.



The Company has the following future commitments associated with its dispensary lease obligations:

Less than one year	\$ 262,794
2 - 5 years	1,524,921
Thereafter	 111,714
Total lease payments	1,899,429
Amount representing interest over the term	 (247,893)
Present value of the net obligation	\$ 1,651,536

The Company utilized certain IFRS 16 exemptions to exclude low-value right-of-use assets and short-term lease arrangements as leases. The Company has a variable lease agreement at NGEV whereby the rent is based on 10% of the net revenue. Variable lease arrangements are recognized as operating lease payments and totalled \$84,635 and were recognized in costs of goods sold in the consolidated statements of operations during the six month period ended June 30, 2021.

#### 10. NOTES PAYABLE

The Company's notes payable consists of the following:

	June 30,	De	cember 31,
	2021		2020
Note payable:			
Land and buildings (1)	\$ 1,096,086	\$	1,118,687
Deferred rent (2)	105,332		131,666
Promissory note (3)	249,088		278,118
Vehicles (4)	 100,205		89,849
Total notes payable	1,550,711		1,618,320
Less current portion:	 (189,606)		(190,974)
Notes payable, long term	\$ 1,361,105	\$	1,427,346

- (1) The Company has a secured note payable outstanding related to the acquisition of land and buildings in Sacramento, California totaling \$1,096,086 at June 30, 2021 (Note 7). The note bears interest at 6% per year, requires monthly payments of principal and interest totaling \$9,314 and matures in April 2036. Interest expense recognized in the 2021 six month period totaled \$33,280 and principal repaid was \$22,602. Principal repayments due in the next 12 months totaling \$47,284 are recorded as current liabilities on the condensed consolidated statement of financial position at June 30, 2021.
- (2) In conjunction with the acquisition of NGEV in 2020, the Company assumed an unsecured deferred rent note payable. The note is non-interest bearing, requires monthly payments of \$4,389 and matures in July 2023. Principal repayments due in the next 12 months totaling \$52,668 are recorded as current liabilities on the condensed consolidated statement of financial position at June 30, 2021.
- (3) Pursuant to the acquisition of NGEV, the Company assumed an unsecured promissory note. The promissory note bears interest at 12% per annum, requires monthly payments of \$7,500 and matures in November 2024. Principal repayments due in the next 12 months totaling \$63,528 are recorded as current liabilities on the condensed consolidated statement of financial position at June 30, 2021.



(4) The Company also has six vehicle acquisition notes payable. The notes payable bear interest ranging from 0% to 4.99% per year, require monthly payments of principal and interest totaling \$2,234 and mature in January 2023, June, July and September 2025 and April 2026. Principal repayments due in the next 12 months totaling \$26,126 are recorded as current liabilities on the consolidated statement of financial position at June 30, 2021.

The following table presents the contractual maturities of the notes payable at June 30, 2021 on an undiscounted basis:

	Land and			eferred	Pro	omissory				
	В	uildings		Rent		Note	V	ehicles		Total
Amounts due										
Less than one year	\$	47,285	\$	52,668	\$	63,528	\$	26,125	\$	189,606
One to three years	\$	223,526	\$	52,664	\$	185,560	\$	38,280	\$	500,030
Four to five years	\$	223,526	\$	-	\$	-	\$	35,800	\$	259,326
Thereafter	\$	601,749	\$		\$		\$	-	\$	601,749
Total maturities at June 30, 2021	\$ :	\$ 1,096,086		105,332	\$	249,088	\$	100,205	\$ :	1,550,711

### 11. SHAREHOLDERS' EQUITY

## (a) Share capital

The Company is authorized to issue an unlimited number of common shares. Holders of common shares are entitled to participate in dividends when declared by the Company.

The Company has the following issued and outstanding common shares:

	June 30, 2021	December 31, 2020
Balance, beginning of period	82,613,028	77,577,212
Issued in equity financings (i)	19,456,750	-
Agents commission (i)	408,000	-
Issued in acquisitions	-	3,712,092
Issued in asset acquisitions	-	669,398
Issued in exchange for services rendered	-	455,036
Exercise of warrants	273,504	-
Exercise of stock options	286,646	199,290
Balance, end of period	103,037,928	82,613,028

- (i) On March 16, 2021, the Company raised gross proceeds of CAD \$15,954,435 via the issuance of 19,456,750 Units. Each Unit was priced at CAD \$0.82 and is comprised of one common share and one-half share purchase warrant with a whole warrant exercisable at \$1.06 until March 16, 2024. The Company issued 1,331,736 broker warrants to the Underwriters and Agents exercisable at CAD \$0.82 until March 16, 2024 and 408,000 Units as partial consideration for their commission. The Company incurred CAD \$1,020,213 of professional fees and commissions related to the financings.
- (ii) The fair value of weighted average fair market value of the Unit warrants and broker warrants is approximately \$0.36 (CAD) and \$0.42 (CAD), respectively, was estimated using the Black-Scholes option-pricing model with the following assumptions: dividend yield nil, expected volatility 78%, risk-free rate 1.00%, expected life 3 years and an estimated forfeiture rate Nil.



## (b) Warrants

	June 30,	December 31,
-	2021	2020
Balance, beginning of period	2,000,000	125,810
Issued in acquisitions	-	1,200,000
Issued in asset acquisitions	-	800,000
Issued in equity financings (Note 11(b)(i))	9,728,375	-
Agents commission (Note 11(b)(i))	204,000	-
Agents warrants (Note 11(b)(i))	1,331,736	-
Exercised	(273,504)	-
Expired		(125,810)
Balance, end of period	12,990,607	2,000,000

	Number	ı	Exercise	Remaing			
Date of Grant	Outstanding	Price (CAD \$)		Price (CAD \$)		Contractual Life	Expiry Date
September 17, 2020	680,480	\$	0.60	0.22	September 17, 2021		
November 11, 2020	1,046,016	\$	0.62	0.31	October 21, 2021		
March 16, 2021	1,331,736	\$	0.82	2.71	March 16, 2024 (i)		
March 16, 2021	9,728,375	\$	1.06	2.71	March 16, 2024 (i)		
March 16, 2021	204,000	\$	1.06	2.71	March 16, 2024		
	12,990,607						

<sup>(</sup>i) If the volume-weighted average price of the common shares on the Canadian Securities Exchange (or any such other stock exchange in Canada as the common shares may trade at the applicable time) is greater than or equal to CAD \$2.12 per common share for a period of 10 consecutive trading days at any time following the date hereof, the Company may, in its sole discretion and upon giving notice to holders of warrants, accelerate the expiry of the warrants to the date that is 30 days following the date of such notice.

### (c) Stock Options

The Company has a stock option plan that provides for the issuance to its directors, officers, employees and consultants options to purchase from treasury a number of common shares not exceeding 10% of the common shares that are outstanding from time to time which is the number of shares reserved for issuance under the plan. The options are non-transferable if not exercised. The exercise price is based on the Company's common shares prior to the day of the grant, which may be different from the closing price of such shares on the day of grant for options granted to date. To date the exercise price has not been materially different from the trading price of the shares on the grant date. A summary of the status of the Company's stock option plan as at June 30, 2021 and December 31, 2020 and changes during the respective periods ended on those dates is presented below:



	June 3	30, 2	.021	Decembe	December 31, 2020				
		Weighted							
	Number of		average	Number of		average			
	options	ex	ercise price	options	exe	ercise price			
			(CAD \$)			(CAD \$)			
Balance, beginning of period	4,162,698	\$	0.77	4,600,218	\$	0.62			
Granted	695,000		0.49	495,000		0.49			
Exercised	(286,646)	)	0.14	(199,287)		0.006			
Cancelled / Expired	(1,889,591)	) _	1.16	(733,233)		0.61			
Balance, end of period	2,681,461	<u>\$</u>	0.64	4,162,698	\$	0.77			
Exercisable, end of period	1,680,799	\$	0.50	3,033,398	\$	0.83			

The weighted average fair market value per option of approximately 0.54 (CAD) was estimated using the Black-Scholes option-pricing model with the following assumptions: dividend yield – nil, expected volatility 78%, risk-free rate – 1.00%, expected life 3 years, an estimated forfeiture rate – 5% and utilizing the graded option method.

The range of exercise prices for the options outstanding and exercisable at June 30, 2021 are as follows:

	Number	ı	Exercise	Remaing	Number	
Date of Grant	Outstanding	Pri	ce (CAD \$)	Contractual Life	Expiry Date	Exerciseable
August 2, 2018	99,643	\$	0.006	2.09	August 2, 2023	99,643
January 15, 2019	173,293	\$	0.96	0.04	July 15, 2021	173,293
March 12, 2019	303,262	\$	0.52	0.67	February 28, 2022	303,263
March 12, 2019	303,262	\$	0.52	0.45	December 12, 2021	303,262
May 30, 2019	362,000	\$	0.52	1.92	May 30, 2023	241,338
October 1, 2019	150,000	\$	0.20	2.25	October 1, 2023	150,000
October 9, 2019	100,000	\$	0.20	0.28	October 9, 2021	100,000
April 8, 2020	100,000	\$	0.15	0.47	December 19, 2021	100,000
October 8, 2020	245,000	\$	0.56	3.28	October 8, 2024	50,000
December 16, 2020	150,000	\$	0.60	3.47	December 16, 2024	62,500
March 17, 2021	140,000	\$	1.05	2.72	March 17, 2024	35,000
March 25, 2021	555,000	\$	1.07	2.74	March 25, 2024	62,500
	2,681,460					1,680,799

Subsequent to the period end, 173,293 options expired with an exercise price of CAD \$0.96.

## (d) Restricted Share Units

At the Company's June 24, 2020 Annual and Special Meeting of Shareholders, the shareholders approved an equity settled Restricted Share Unit plan ("RSU") for certain officers and employees. The units are awarded at no



cost to the recipient and the fair market value determined at the grant date is expensed uniformly over their vesting period. The fair market value of the award is based on the trading price for the shares on the Canadian Stock Exchange ("CSE") on the grant date. RSU expense is recognized over the vesting period with a related credit to contributed surplus. Vibe recognizes the expense based on the best available estimate of the number of RSUs expected to vest and revises the estimate if necessary. Upon redemption of RSUs, the contributed surplus balance is reduced through a credit to shareholders' capital. The weighted average fair value of RSUs granted during the year ended December 31, 2020, were \$0.55 (CAD) per RSU and in March 2021, 100,000 RSU's were granted at \$1.07 (CAD) per RSU based on the Company's share price at the date of grant.

### 12. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, other current assets, accounts payable and notes payable.

### Fair Value Measurements

All financial instruments are initially recognized at fair value and subsequently measured at amortized costs.

The carrying value of cash and cash equivalents, accounts receivable, other current assets and accounts payable approximately their value due to the short period to maturity of these instruments.

The fair value of the notes payable approximates the fair value as they are based on amounts owed to third parties and estimated internal borrowing rates (in the case of lease obligations) using current market price indicators.

### **Liquidity Risk**

Liquidity risk includes the risk that, as a result of the Company's operational liquidity requirements:

- The Company will not have sufficient funds to settle a transaction on the due date;
- The Company will be forced to sell financial assets at a value which is less than what they are worth; or
- The Company may be unable to settle or recover a financial asset.

The Company's approach to managing liquidity is to ensure, within reasonable means, sufficient liquidity to meet its liabilities when due, under both normal and unusual conditions, without incurring unacceptable losses or jeopardizing the Company's business objectives. The Company prepares annual capital expenditure budgets which are monitored regularly and updated as considered necessary. Store sales are monitored daily to provide current cash flow estimates and the Company utilizes authorizations for expenditures on projects to manage capital expenditures. Any funding shortfall may be met in several ways, including, but not limited to, the issuance of new debt or equity instruments or expenditure reductions.



The Company is obligated to the following contractual maturities of undiscounted cash flows:

	ı	Less than		than One to Four to									
	(	one year		one year		one year T		Three years		Five years		ereafter	Total
Financial liability													
Accounts payable	\$	2,842,519	\$	-	\$	-	\$	-	\$ 2,842,519				
Notes payable		189,606		500,030	2	259,326		601,749	1,550,711				
Lease obligations		262,794		900,150	(	524,771		111,714	1,899,429				
Total contractual maturities	\$	3,294,919	\$ 1,400,180		\$ 884,097		\$	713,463	\$ 6,292,659				

#### Market Risk

Market risk is comprised of four components: currency risk, interest rate risk concentration risk and price risk.

### i) Foreign Currency Exchange Risk

The Company operates on an international basis and therefore foreign exchange risk exposures arise from transactions denominated in currencies other than the United States Dollar. The Company is exposed to foreign currency fluctuations as it holds cash and incurs expenditures in administrative costs in foreign currencies. The Company incurs expenditures in Canadian Dollars and United States Dollars and is exposed to fluctuations in exchange rates in these currencies. There are no exchange rate contracts in place at June 30, 2021 and December 31, 2020.

### ii) Interest Risk

Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. The Company is not currently exposed to interest rate risk as its notes payable bear interest at fixed rates.

## iii) Concentration Risk

The Company only operates in California. Should economic conditions deteriorate within that region, its results of operations and financial position would be negatively impacted.

## iv) Price Risk

Price risk is the risk of variability in fair value due to movements in market prices. Please refer to Note 5 Biological Assets for the Company's assessment of certain changes in the fair value assumption used in the calculation of biological asset values.



#### 13. CAPITAL MANAGEMENT

The Company views its capital as the combination of notes payable and shareholders' equity. The Company's objectives when managing its capital are to safeguard assets while maximizing the growth of the business and return to shareholders. The overall capitalization of the Company is as follows:

	June 30,	December 31,
	2021	2020
Notes payable, including current portion		\$ 1,618,320
Shareholders' equity	22,428,147	10,110,215
Total capital	\$ 23,978,858	\$ 11,728,535

In order to meet the Company's capital management objectives, management is focused on several specific strategies as follows:

- (i) Ensuring the Company has the financing capacity to continue to execute on opportunities to increase overall market share through strategic acquisitions.
- (ii) Maintaining a strong capital base to secure investor, creditor and market confidence and ensure the Company's strategic objectives are met.
- (iii) Providing shareholder return through profitable business opportunities that grow the Company and benefit other stakeholders, while also safeguarding the entity's ability to continue as a going concern.

In managing the Company's capital, management considers current economic conditions, the risk characteristics of the underlying assets and the Company's planned capital requirements, within guidelines approved by its Board of Directors. Total capitalization is maintained or adjusted by issuing new debt or equity securities when opportunities are identified and through the disposition of under-performing assets to reduce debt or equity when required.

#### 14. CONTINGENCIES

The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines or restrictions on its operations and losses of permits that could cause the Company to cease operations. While management believes that the Company is compliant with applicable local and state regulations at June 30, 2021, medical and adult use cannabis regulations continue to evolve and are subject to differing interpretations. Accordingly, the Company may be subject to regulatory fines, penalties or operating restrictions in the future.

Although the possession, cultivation and distribution of cannabis for recreational and medical use is permitted in California, cannabis is a Schedule-I controlled substance and its use remains a violation of federal law. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in the Company's inability to proceed with its business plans. In addition, the Company's assets, including real property, cash, equipment and other goods, could be subject to asset forfeiture because cannabis is still federally illegal.



From time to time, the Company may be involved in litigation or has claims sought against it in the normal course of business operations. Management of the Company is aware of one claim whereby former consultants are demanding to exercise stock options granted. The Company's position is the options were terminated.

Under the terms of certain agreements and the Company's by-laws the Company indemnifies individuals who have acted at the Company's request to be a director and/or officer of the Company, to the extent permitted by law, against any and all damages, liabilities, costs, charges or expenses suffered by or incurred by the individuals as a result of their service.

### 15. SEGMENTED DISCLOSURE

The Company has five reportable operating segments for the three and six month period ended June 30, 2021: Dispensaries, Cultivation, Distribution, Real Estate and Corporate. The Company, through its operating segments, is engaged primarily in the retail sale and cultivation of cannabis. Management will regularly review the operating results of each operating segment to assess the operating segments' profitability and, correspondingly, the ability of each operating segment to sustain capital, enable future growth through capital investment and to repay debt.

The following tables show information regarding the Company's segments as at and for the three and six month period ended June 30, 2021.

									Consolidating					
As at June 30, 2021	Disp	ensaries	Cı	ultivation	D	istribution	R	teal Estate		Corporate	Α	djusmtents		Total
Assets														
Current assets														
Cash and cash equivalents	\$ 2	2,046,179	\$	27,627	\$	40,735	\$	31,500	\$	10,846,275			\$	12,992,316
Accounts receivable		116,200		1,439,958		496,696		-		34,386		(1,865,006)		222,234
Inventory	1	1,822,956		164,878		1,890,673		-		13,856		-		3,892,363
Biological assets		-		483,501		-		-		-				483,501
Other current assets		378,029		99,928	_	19,641	_	3,000	_	15,688	_	-	_	516,286
Total current assets	\$ 4	4,363,364	\$	2,215,892	\$	2,447,745	\$	34,500	\$	10,910,205	\$	(1,865,006)	\$	18,106,700
Intangible assets and goodwill	7	7,601,134		391,055		312,708		-		-		-		8,304,897
Property and equipment		916,155		1,878,639		564		2,648,720		2,509		-		5,446,587
Right-of-use assets	1	1,516,075				118,193		-				-	_	1,634,268
Total assets	\$ 14	4,396,728	\$	4,485,586	\$	2,879,210	\$	2,683,220	\$	10,912,714	\$	(1,865,006)	\$	33,492,452
Liabilities														
Current liabilities														
Total current liabilities	\$ 3	3,291,017	\$	207,951	\$	1,678,422	\$	47,282	\$	4,338,150	\$	(1,865,006)	\$	7,697,816
Notes payable		71,498		240,804				1,048,803		-		-		1,361,105
Lease obligations	1	1,108,431		-		83,467		-		-		-		1,191,898
Deferred tax liability		750,297		63,189		-			_	_		-		813,486
Total liabilities	\$ 5	5,221,243	\$	511,944	\$	1,761,889	\$	1,096,085	\$	4,338,150	\$	(1,865,006)	\$	11,064,305



For the Three Months Ended June 30, 2021	Dispensaries	Cultivation	Distribution	Real Estate	Canada	Consolidating Adjustments	Total
Revenue	\$ 7,440,271	\$ 467,390	\$ 351,381	\$ -	\$ -	\$ (467,352)	\$ 7,791,690
Cost of goods sold	\$ 4,949,599	\$ 489,469	\$ 298,362	\$ -	\$ -	\$ (475,434)	5,261,996
Gross margin before biological asset adjustments	2,490,672	(22,079)	53,019		-	8,082	2,529,694
Net effect of adjustments for biological assets		33,683				(8,082)	25,601
Gross margin	2,490,672	11,604	53,019	-	-	-	2,555,295
Operating expenses							
General and administrative	580,373	(23,377)	47,945	-	167,937	-	772,878
Sales, security and marketing	772,742	53,521	59,919	-	-	-	886, 182
Stock-based compensation	-	-	-	-	143,661	-	143,661
Depreciation and amortization	239,651	33,766	(2,244)	11,963	338		283,474
	1,592,766	63,910	105,620	11,963	311,936		2,086,195
Other expenses (income)	26,444	7,865	-	16,556	34,797	-	85,662
Income (loss) before income taxes	871,462	(60,171)	(52,601)	(28,519)	(346,733)	-	383,438
Income tax expense (recovery)							
Current		-		-	509,766	-	509,766
Deferred	(21,958)	(3,545)					(25,503)
Income tax expense (recovery)	(21,958)	(3,545)			509,766		484,263
Net income (loss) for the period	\$ 893,420	\$ (56,626)	\$ (52,601)	\$ (28,519)	\$ (856,499)	\$ -	\$ (100,825)
						Consolidating	
For the six month ended June 30, 2021	Dispensaries	Cultivation	Distribution	Real Estate	Corporate	Consolidating Adjustments	Total
For the six month ended June 30, 2021 Revenue	<b>Dispensaries</b> \$ 14,530,201		Distribution \$ 899,198			Adjustments	
·		Cultivation \$ 1,136,026 1,054,408				_	
Revenue	\$ 14,530,201	\$ 1,136,026	\$ 899,198			Adjustments \$ (1,231,000)	\$ 15,334,425
Revenue Cost of goods sold	\$ 14,530,201 9,600,886	\$ 1,136,026 1,054,408	\$ 899,198 732,513			Adjustments \$ (1,231,000) (1,064,000)	\$ 15,334,425 10,323,807
Revenue Cost of goods sold Gross margin before biological asset adjustments	\$ 14,530,201 9,600,886 4,929,315	\$ 1,136,026 1,054,408 81,618	\$ 899,198 732,513 166,685		\$ -	\$ (1,231,000) (1,064,000) (167,000)	\$ 15,334,425 10,323,807 5,010,618
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets	\$ 14,530,201	\$ 1,136,026 1,054,408 81,618 (57,611)	\$ 899,198		\$ -	\$ (1,231,000) (1,064,000) (167,000)	\$ 15,334,425 10,323,807 5,010,618 109,389
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin	\$ 14,530,201	\$ 1,136,026 1,054,408 81,618 (57,611)	\$ 899,198		\$ -	\$ (1,231,000) (1,064,000) (167,000)	\$ 15,334,425 10,323,807 5,010,618 109,389
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007	\$ 899,198 732,513 166,685 - 166,685	\$ - - - -	\$ - - - - -	\$ (1,231,000) (1,064,000) (167,000)	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855	\$ - - - -	\$ - - - - -	\$ (1,231,000) (1,064,000) (167,000)	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855	\$	\$	\$ (1,231,000) (1,064,000) (167,000)	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855	\$ - - - - 10,522 - -	\$ - - - - - - 429,178 - 241,601	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154 - 410,552	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994 - 85,953	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855 - 12,241	\$ - - - - 10,522 - - 23,795	\$ - - - - - - 429,178 - 241,601 663	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601 533,204
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation Depreciation and amortization	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154 - 410,552 3,008,339	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994 - 85,953 213,404	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855 - 12,241	\$ - - - - 10,522 - - - 23,795 34,317	\$ - - - - - - 429,178 - 241,601 663 671,442	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601 533,204 4,076,741
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation Depreciation and amortization Other expenses (income)	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154 - 410,552 3,008,339 42,759	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994 - 85,953 213,404 16,178	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855 - 12,241 149,239	\$ - - - - 10,522 - - 23,795 34,317 33,280	\$ - - - - - - 429,178 - 241,601 663 671,442 34,642	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601 533,204 4,076,741 126,859
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation Depreciation and amortization  Other expenses (income) Income (loss) before income taxes Income tax expense (recovery) Current	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154 - 410,552 3,008,339 42,759 1,878,217	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994 - 85,953 213,404 16,178 (205,575)	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855 - 12,241 149,239	\$ - - - - 10,522 - - 23,795 34,317 33,280	\$ - - - - - - 429,178 - 241,601 663 671,442 34,642	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601 533,204 4,076,741 126,859 916,407
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation Depreciation and amortization  Other expenses (income) Income (loss) before income taxes Income tax expense (recovery)	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154 - 410,552 3,008,339 42,759	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994 - 85,953 213,404 16,178 (205,575)	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855 - 12,241 149,239	\$ - - - - 10,522 - - 23,795 34,317 33,280	\$ - - - - - - 241,601 663 671,442 34,642 (706,084)	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601 533,204 4,076,741 126,859 916,407 998,766 (49,779)
Revenue Cost of goods sold Gross margin before biological asset adjustments Net effect of adjustments for biological assets Gross margin Operating expenses General and administrative Sales, security and marketing Stock-based compensation Depreciation and amortization  Other expenses (income) Income (loss) before income taxes Income tax expense (recovery) Current	\$ 14,530,201 9,600,886 4,929,315 - 4,929,315 960,633 1,637,154 - 410,552 3,008,339 42,759 1,878,217	\$ 1,136,026 1,054,408 81,618 (57,611) 24,007 56,457 70,994 - 85,953 213,404 16,178 (205,575)	\$ 899,198 732,513 166,685 - 166,685 83,143 53,855 - 12,241 149,239	\$ - - - - 10,522 - - 23,795 34,317 33,280	\$ - - - - - - 241,601 663 671,442 34,642 (706,084)	\$ (1,231,000) (1,064,000) (167,000) 	\$ 15,334,425 10,323,807 5,010,618 109,389 5,120,007 1,539,933 1,762,003 241,601 533,204 4,076,741 126,859 916,407



## 16. SUBSEQUENT EVENTS

Except as disclosed elsewhere in these consolidated financial statements the Company has the following subsequent events:

Subsequent to June 30, 2021, 15,145 of the warrants issued in the CAHC and PAHC transactions were exercised.

On July 20, 2021, Vibe entered into a purchase and sale agreement to acquire 10 acres of land in Monterey County, California, for a total consideration of \$5.1 million. The acquisition closed on August 19, 2021.